

Variant: NM_004985.4(KRAS):c.101C>T (p.Pro34Leu)

CA235301 [↗](#)

40454 (ClinVar) [↗](#)

Gene: KRAS ([HGNC:3845](#))

Condition: Noonan syndrome ([MONDO:0018997](#))

Inheritance Mode: Autosomal dominant inheritance

UUID: bf62d2f1-6047-4d6b-9cb9-dfdab291cdfb

Approved on: 2017-04-03

Published on: 2018-12-10

HGVS expressions

NM_004985.4:c.101C>T

NM_004985.4(KRAS):c.101C>T (p.Pro34Leu)

NC_000012.12:g.25245284G>A

CM000674.2:g.25245284G>A

NC_000012.11:g.25398218G>A

CM000674.1:g.25398218G>A

NC_000012.10:g.25289485G>A

NG_007524.1:g.10637C>T

NG_007524.2:g.10720C>T

ENST00000556131.2:c.101C>T

ENST00000557334.6:c.101C>T

ENST00000685328.1:c.101C>T

ENST00000686877.1:c.101C>T

ENST00000686969.1:c.101C>T

ENST00000687356.1:c.101C>T

ENST00000688940.1:c.101C>T

ENST00000690804.1:c.101C>T

ENST00000692768.1:c.-88+5467C>T

ENST00000693229.1:c.101C>T

ENST00000256078.10:c.101C>T

ENST00000311936.8:c.101C>T

ENST00000256078.8:c.101C>T

ENST00000311936.7:c.101C>T

ENST00000556131.1:c.101C>T

ENST00000557334.5:c.101C>T

NM_033360.3:c.101C>T

NM_001369786.1:c.101C>T

NM_001369787.1:c.101C>T

NM_004985.5:c.101C>T

NM_033360.4:c.101C>T

Pathogenic

Met criteria codes **7**

PS3_Supporting PS4_Moderate PP2

PP3 PM5 PM2_Supporting

PS2_Very Strong

Expert Panel

RA_Sopathy VCEP [↗](#)

Criteria Specification Information

Not Met criteria codes 3

BA1 BS1 BP4

Evidence Links 0

[Criteria Specification: ClinGen RASopathy Expert Panel](#)

Specifications to the ACMG/AMP Variant Interpretation

Guidelines for KRAS Version 2.1.0

[Criteria Specification Approval History](#)

[Criteria Specifications for this VCEP](#)

Evidence submitted by expert panel

RASopathy VCEP

The c.101C>T variant in the KRAS gene is a missense variant predicted to cause substitution of proline by leucine at amino acid 34 (p.Pro34Leu). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). The computational predictor REVEL gives a score of 0.867 supporting a deleterious impact to KRAS function (PP3). The variant is located in the KRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2). A different pathogenic missense variant has been previously identified at this codon of KRAS (c.101C>G (p.Pro34Arg)) which may indicate that this residue is critical to the function of the protein (PM5; ClinVar 12590). This variant has been reported in 3 individuals as two confirmed de novo occurrences and one unconfirmed de novo occurrence with clinical features of a RASopathy (PS4_Moderate, PS2_VeryStrong; PMIDs: 17056636, 30732632, ClinVar SCV: SCV000207884.10, Internal lab contributors: GeneDx). A RAS activation assay showed that this variant led to increased RAS activation (PS3_Supporting; PMID: 20949621). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant RASopathies based on the ACMG/AMP criteria applied, as specified by the ClinGen RASopathy Variant Curation Expert Panel: PS2_VeryStrong, PS4_Moderate, PM5, PS3_Supporting, PM2_Supporting, PP2, PP3 (Specification Version 2.1, 09/17/2024)

Met criteria codes

PS3_Supporting			A RAS activation assay showed that this variant led to increased RAS activation (PS3_Supporting; PMID: 20949621).
PS4_Moderate			This variant has been reported in 3 individuals with clinical features of a RASopathy (PS4_Moderate, PMIDs: 17056636, 30732632, ClinVar SCV: SCV000207884.10, Internal lab contributors: GeneDx)
PP2			The variant is located in the KRAS gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID 29493581).
PP3			The computational predictor REVEL gives a score of 0.867 supporting a deleterious impact to KRAS function.
PM5			A different pathogenic missense variant (c.101C>G (p.Pro34Arg)) has been previously identified at this codon of KRAS which may indicate that this residue is critical to the function of the protein (PM5; ClinVar 12590).
PM2_Supporting			This variant was absent from gnomAD v4.1.0 meeting PM2_Supporting
PS2_Very Strong			The c.101C>T (p.Pro34Leu) variant in KRAS has been reported as a confirmed de novo occurrence in 2 patients and an unconfirmed de novo occurrence in 1 patient with clinical features of a RASopathy (PS2_VeryStrong; PMID 17056636, 30732632, ClinVar SCV: SCV000207884.10, Internal lab contributors: GeneDx).

Not Met criteria codes

BA1			This variant was absent from gnomAD v4.1.0 meeting PM2_Supporting
BS1			This variant was absent from gnomAD v4.1.0 meeting PM2_Supporting
BP4			The computational predictor REVEL gives a score of 0.867 supporting a deleterious impact to KRAS function.

Curation History 		
 Showing 1 to 3 of 3 rows		

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.